Literature DB >> 17332487

TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells.

Andreas Zirlik1, Udo Bavendiek, Peter Libby, Lindsey MacFarlane, Norbert Gerdes, Joanna Jagielska, Sandra Ernst, Masanori Aikawa, Hiroyasu Nakano, Erdyni Tsitsikov, Uwe Schönbeck.   

Abstract

OBJECTIVE: Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis. METHODS AND
RESULTS: CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease.
CONCLUSIONS: These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332487     DOI: 10.1161/ATVBAHA.107.140566

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

1.  Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis.

Authors:  Robert C Huebert; Kumaravelu Jagavelu; Ann F Liebl; Bing Q Huang; Patrick L Splinter; Nicholas F LaRusso; Raul A Urrutia; Vijay H Shah
Journal:  Lab Invest       Date:  2010-07-19       Impact factor: 5.662

2.  Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.

Authors:  Archita Das; Varadarajan Sudhahar; Masuko Ushio-Fukai; Tohru Fukai
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

Review 3.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  TRAF6 protein couples Toll-like receptor 4 signaling to Src family kinase activation and opening of paracellular pathway in human lung microvascular endothelia.

Authors:  Anguo Liu; Ping Gong; Sang W Hyun; Kent Z Q Wang; Elizabeth A Cates; Darren Perkins; Douglas D Bannerman; Adam C Puché; Vladimir Y Toshchakov; Shengyun Fang; Philip E Auron; Stefanie N Vogel; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

5.  Directing TRAF-ic: cell-specific TRAF6 signaling in chronic inflammation and atherosclerosis.

Authors:  Ellen O Weinberg; Caroline Attardo Genco
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

6.  CD40 activation in human pancreatic islets and ductal cells.

Authors:  D Klein; F Timoneri; H Ichii; C Ricordi; R L Pastori
Journal:  Diabetologia       Date:  2008-07-26       Impact factor: 10.122

7.  cIAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand.

Authors:  Alban Dupoux; Jessy Cartier; Séverine Cathelin; Rodolphe Filomenko; Eric Solary; Laurence Dubrez-Daloz
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

8.  Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease.

Authors:  Amanda K Huber; Fred D Finkelman; Cheuk Wun Li; Erlinda Concepcion; Eric Smith; Eric Jacobson; Rauf Latif; Mehdi Keddache; Weijia Zhang; Yaron Tomer
Journal:  J Immunol       Date:  2012-08-10       Impact factor: 5.422

9.  Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells.

Authors:  Jose-Andres C Portillo; Jennifer A Greene; Isaac Schwartz; Maria Cecilia Subauste; Carlos S Subauste
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

10.  Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.

Authors:  Esther Lutgens; Dirk Lievens; Linda Beckers; Erwin Wijnands; Oliver Soehnlein; Alma Zernecke; Tom Seijkens; David Engel; Jack Cleutjens; Anna M Keller; Shalin H Naik; Louis Boon; Hafid Ait Oufella; Ziad Mallat; Cory L Ahonen; Randolph J Noelle; Menno P de Winther; Mat J Daemen; Erik A Biessen; Christian Weber
Journal:  J Exp Med       Date:  2010-01-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.